BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Paclitaxel: trial readouts and FDA decisions

22 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 21 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Akeso, Merck Sharp & Dohme LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., AstraZeneca, Tesaro, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Mabscale, LLC, Tesaro, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Mabscale, LLC, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., RemeGen Co., Ltd., Eikon Therapeutics, Suzhou Suncadia Biopharmaceuticals Co., Ltd., GlaxoSmithKline, Nanjing Leads Biolabs Co.,Ltd, CanariaBio Inc., NATCO Pharma Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, AskGene Pharma, Inc., Shanghai Jiaolian Drug Research and Development Co., Ltd, CStone Pharmaceuticals, Gilead Sciences, Jiangsu HengRui Medicine Co., Ltd., Bristol-Myers Squibb, Innovent Biologics (Suzhou) Co. Ltd., Shanghai Runshi Pharmaceutical Technology Co., Ltd, Qilu Pharmaceutical Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., Arcus Biosciences, Inc., Bio-Thera Solutions, Daiichi Sankyo, Regeneron Pharmaceuticals, Genmab, DualityBio Inc., Actuate Therapeutics Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-20 est.P3Merck Sharp & Dohme LLC MRKNCT04634877 Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer Endometrial Neoplasmsactive not recruiting990
2026-11-26 est.P3Tesaro, Inc.NCT03981796 A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced EndomeNeoplasmsactive not recruiting785
2026-12 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT05054439 A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCCHead and Neck Squamous Cell Carcinomaactive not recruiting45
2026-12 est.P3Mabscale, LLCNCT05654454 A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung CancerNon-Small Cell Lung Cancerrecruiting620
2026-12 est.P1/P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06202261 A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast CancerMetastatic Breast Cancer; Recurrent Breast Cancer; Advanced Malignanciesrecruiting154
2026-12 est.P2/P3RemeGen Co., Ltd.NCT06221748 DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapGastric Cancer; Gastroesophageal Junction Adenocarcinomarecruiting90
2026-12 est.P2Eikon Therapeutics EIKNNCT06246110 A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCNSCLCactive not recruiting70
2026-12 est.P1/P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06840002 A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian CancerOvarian Cancerrecruiting150
2026-12 est.P1/P2AkesoNCT06943820 AK129 Combination Therapy for Advanced Solid TumorsNon-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC); Colorectal recruiting230
2026-12-14 est.P2GlaxoSmithKlineNCT06317311 A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial CancerCarcinomaactive not recruiting41
2026-12-24 est.P2Nanjing Leads Biolabs Co.,LtdNCT06783647 A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]Advanced Solid Tumourrecruiting250
2026-12-26 est.P3CanariaBio Inc.NCT04498117 Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking SurgeryCarcinoma, Ovarian Epithelial; Ovarian Neoplasms; Ovarian Cancer; Ovarian Serous Adenocarcinoma; Falactive not recruiting615
2026-12-30 est.P2AkesoNCT05227664 A Study of AK117/AK112 in Metastatic Triple-Negative Breast CancerMetastatic Triple-negative Breast Cancer; Locally Advanced Triple-negative Breast Canceractive not recruiting120
2026-12-30 est.P2NATCO Pharma Ltd.NCT05283226 Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Carcinoma; Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomarecruiting21
2026-12-30 est.P3Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT06751485 JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian CancerOvarian Cancer; Primary Peritoneal; Fallopian Tube Cancersnot yet recruiting430
2026-12-31 est.P1/P2AskGene Pharma, Inc.NCT05867420 A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.Advanced Solid Tumorsrecruiting594
2026-12-31 est.P2Shanghai Jiaolian Drug Research and Development Co., LtdNCT06434610 A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.Platinum-resistant Recurrent Ovarian Cancerrecruiting90
2027-01 est.P1/P2CStone PharmaceuticalsNCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid TumorsAdvanced Solid Tumorsrecruiting800
2027-02 est.P3Gilead Sciences GILDNCT05382286 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally AdTriple Negative Breast Cancer; PD-L1 Positiveactive not recruiting443
2027-02 est.P1/P2Jiangsu HengRui Medicine Co., Ltd.NCT07136142 A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid TumorsMalignant Solid Tumorrecruiting150
2027-02-05 est.P2Bristol-Myers Squibb BMYNCT06946797 A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously UnNon-Small Cell Lung Canceractive not recruiting76
2026-12-30 est.P3Innovent Biologics (Suzhou) Co. Ltd.NCT06238843 A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinomaactive not recruiting464

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-13 est.P1/P2Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06682611 Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.Unresectable Locally Advanced or Metastatic Solid Tumorsnot yet recruiting380
2026-11 est.P3AkesoNCT06341335 A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction AdenocarcinomaGastric and Gastroesophageal Junction Adenocarcinomarecruiting506
2026-10-19P3Merck Sharp & Dohme LLC MRKNCT06356311 A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Gastroesophageal Canceractive not recruiting473
2026-10 est.P1/P2Qilu Pharmaceutical Co., Ltd.NCT07256782 A Study of QLC5508 Combinations in Patients With Advanced Solid TumorsAdvanced Solid Tumorrecruiting444
2026-10 est.P2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT07229729 A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung CancerNon-small Cell Lung Cancerrecruiting300
2026-09-30 est.P3Innovent Biologics (Suzhou) Co. Ltd.NCT05116462 Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung CancerNon-Small Cell Lung Canceractive not recruiting506
2026-09-17P2Arcus Biosciences, Inc. RCUSNCT04736173 Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerNon Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Cancompleted169
2026-09 est.P2/P3Bio-Thera SolutionsNCT06123884 BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical CancerCervical Cancerrecruiting526
2026-08-31 est.P3Daiichi SankyoNCT04704934 Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-CGastric Cancer, Adenocarcinoma; Gastroesophageal Junction Adenocarcinomaactive not recruiting490
2026-08-24 est.P2Regeneron Pharmaceuticals REGNNCT06161441 A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in AResectable Non-small Cell Lung Canceractive not recruiting195
2026-08-18P3Genmab GMABNCT06619236 Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian CancerPlatinum-resistant Ovarian Canceractive not recruiting584
2026-08-17P3AstraZeneca AZNNCT05984277 A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.Metastatic Non-small Cell Lung Canceractive not recruiting895
2026-08-12P3DualityBio Inc.NCT06018337 A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)Metastatic Breast Canceractive not recruiting541
2026-07 est.P3Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06738251 A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial CarcinomaAdvanced Urothelial Carcinomarecruiting402
2026-07 est.P2AkesoNCT04736823 A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLCNSCLCactive not recruiting265
2026-06-30 est.P1/P2AkesoNCT05904379 AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung CancerAdvanced Non-small-cell Lung Canceractive not recruiting233
2026-06-15P3Merck Sharp & Dohme LLC MRKNCT05298423 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent ChemoraCarcinoma, Non-Small-Cell Lungcompleted610
2026-06 est.P2Actuate Therapeutics Inc. ACTUNCT03678883 9-ING-41 in Patients With Advanced CancersCancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractoryactive not recruiting350
2026-05-31 est.P3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06394492 SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian CancerOvarian Cancerrecruiting440
2026-05-31P3AstraZeneca AZNNCT06346392 AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction AdGastric Cancer; Gastroesophageal Junction Canceractive not recruiting594
2026-05-31P2AkesoNCT05932212 AK104 for Recurrent or Metastatic Vulvar CancerVulvar Cancerterminated20

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.